Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 24Phase 1/2 17Phase 3 5Phase NA 4Phase 4 2Phase 2/3 1

Status

Completed 66Recruiting 25Unknown 22Active not recruiting 21Terminated 17Withdrawn 5Not yet recruiting 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2CNS 1

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

Rituximab 2Dexamethasone 2siltuximab 1pomalidomide 1parsaclisib 1obinutuzumab 1fludarabine 1elotuzumab 1daratumumab 1carfilzomib 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Temozolomide 1Prednisone 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Recurrence × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT06232707 2024-05-31

ALUMMINATE

Celgene

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Incyte Corporation

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Burzynski Research Institute

Phase 3 Withdrawn
CNS

Recurrence, Optic Nerve Glioma

NCT01266811 2013-01-28

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 3 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡